COG AALL0434 PROTOKOLÜ

Kaynaklar:

1- Winter SS, Dunsmore KP, Devidas M, et al. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children’s Oncology Group Study AALL0434. Pediatr Blood Cancer. 2015;62:1176-183. 

2-  Winter SS, Dunsmore KP, Devidas M, et al. Improved survival for children and young adults with T-lineage acute lymphoblastic leukemia: Results from the Children’s Oncology Group AALL0434 methotrexate randomization. J Clin Oncol. 2018;36:2926-2934.

3-Buie LW, Epstein SS, Lindley CM: Nelarabine: A novel purine antimetabolite antineoplastic agent. Clin Ther 29: 1887-1899.

3-Kurtzberg J, Ernst TJ, Keating MJ, et al: Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 23: 3396-3403, 2005.

4-Berg SL, Blaney SM, Devidas M, et al: Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: A report from the Children’s Oncology Group. J Clin Oncol 23: 3376-3382, 2005 

5-DeAngelo DJ, Yu D, Johnson JL, et al: Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. Blood 109:5136-5142, 2007.

6-Kuhlen M, Bleckmann K, Möricke A, et al: Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy. Br J Haematol 179:272-283, 2017